Tremfya® Alternatives

Tremfya, an interleukin inhibitor, is indicated for the treatment of plaque psoriasis or psoriatic arthritis in adults. Patients can learn to self-administer Tremfya subcutaneously every eight weeks, and the most common side effects are injection site reactions and an elevated risk of infection.

Tremfya is FDA approved for the following indications: Plaque Psoriasis and Psoriatic Arthritis.

Cosentyx is a monoclonal antibody treatment option for several conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and others. Following the initial loading dose, subcutaneous injection of Cosentyx is required every four weeks, but patients can typically be taught to self-administer using the Sensoready pen or prefilled syringe. Nasopharyngitis and an elevated risk of infection are the most frequently reported side effects.

Cosentyx is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondylarthritis, and Enthesitis-related Arthritis.